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Br J Clin Pharmacol. 2019;1–11.Aims: With a prevalence of 16%, diabetes mellitus (DM) is one of the most fre-
quent non‐communicable comorbidities of tuberculosis (TB). DM is a major risk factor
for adverse TB outcomes and may require personalized TB drug dosing regimens.
However, information on the inclusion of DM in TB drug trials is lacking. We aimed
to assess the percentage of recent TB drug efficacy trials that included DM patients.
Methods: A systematic review was performed and reported according to PRISMA
guidelines. PubMed, Science Direct, and ClinicalTrials.gov databases were systemati-
cally searched for TB drug trials published between 1 January 2012 and 12
September 2017. Primary outcome was the percentage of TB drug trials performed
around the world that included DM patients.
Results: Out of the included 41 TB drug trials, 12 (29.3%) reported DM comorbidity
among the study participants. Nine trials (21.9%) excluded all patients with DM
comorbidity, ten (24.4%) excluded only insulin‐dependent or uncontrolled DM, and
10 (24.4%) did not mention whether DM was included or excluded. Of the 12 trials
that included DM comorbidity, the majority did not report the diagnostic criteria for
DM and none reported outcomes in the DM subpopulation. Inclusion of DM was
higher in drug‐resistant‐TB trials (67%, P = .003, vs drug‐susceptible) and trials per-
formed in Asia (60%, P = .006, vs Africa).
Conclusions: Fewer than 1/3 recent TB drug trials reported the inclusion of DM.
To better reflect real‐world DM prevalence and differential TB drug effectiveness,
inclusion of DM patients requires increased attention for future TB drug trials.
KEYWORDS
diabetes, drug trials, review, tuberculosis- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
e Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any
d and is not used for commercial purposes.
armacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.
wileyonlinelibrary.com/journal/bcp 1
What is already known about this subject
• Globally, around 16% of tuberculosis (TB) patients suffer
from comorbid diabetes mellitus
• Diabetes is a risk factor for TB, altered pharmacokinetics
and can thus impact pharmacological TB treatment
outcomes
• In recent years, multiple TB drug trials have been
performed, yet a systematic overview of the inclusion
of diabetes comorbidity and potential differential
outcomes within these trials is lacking.
What this study adds
• This systematic review provides an overview of diabetes
inclusion in recent TB drug trials performed around the
world
• Of the 41 studies included, <1/3 TB drug trials reported
the inclusion of patients with diabetes
• A total of 12 studies (29%) reported the inclusion of
patients with diabetes, yet the vast majority of TB drug
trials did not report the diagnostic criteria for diabetes
• None of the studies reported differential outcomes for
the TB–diabetes overlap subpopulation, warranting
increased attention on the design and analyses of future
TB drug trials
2 LUTFIANA ET AL.1 | INTRODUCTION
The dual burden of tuberculosis (TB) and diabetes mellitus (DM) is a
major global public health problem.1 In 2017, the World Health Orga-
nization reported 10 million cases of TB and 1.3 million TB‐related
deaths.2 Approximately 415 million people worldwide live with DM
and another 318 million people have impaired glucose tolerance—a
marker for future diabetes.3 By 2040, these numbers are likely to grow
to 642 million and 481 million, respectively.4
The global burden of TB‐DM overlap is high, with a prevalence of
16% globally, 17% in Asia, 7% in Africa, 24% in North America, 23% in
Oceania, 11% in South America, and 6% in Europe.1 The International
Diabetes Federation (IDF) estimates that 46% of diabetes cases world-
wide (around 175 million) are not diagnosed, with the highest propor-
tions concentrated in Africa (62%) and southeast Asia (54%),
coinciding with the greatest TB burden. Globally, 84% of all people
with undiagnosed diabetes live in low‐income and middle‐income
countries where the management of these people is rarely optimal.5
DM could severely threaten TB control and may become most pro-
found in resource‐poor areas where TB thrives.6
A systematic review and meta‐analysis of studies published
between 1980–2010 reported that DM is associated with 69% higher
risk of death and increased risk of TB relapse thanTB patients without
DM.7 Since 2010, several large cohort studies reported unfavourable
effects of DM onTB outcomes. DM was associated with more severe
clinical manifestations of TB such as higher frequency of cavities on
chest X‐ray and higher hospitalization rates.8-10 Patients with DM
were more likely to have up to 2 times higher TB reactivation, recur-
rence, and relapse.8-11 TB‐DM patients were more likely to have
delayed sputum conversion and higher probability of treatment fail-
ure.8,9,12 A recent systematic review showed that glycaemic control
has a favourable effect on TB treatment outcomes and, conversely,
uncontrolled DM or poor glycaemic control (i.e. HbA1c > 7%) was
associated with delayed sputum conversion.13,14
Early screening for TB‐DM comorbidity can help clinicians to act
promptly, thereby resulting in improved TB treatment outcomes.15
Notably, given the profound impact of DM comorbidity on TB treat-
ment outcomes and the call for intensified precision drug therapy, this
comorbidity should receive higher priority in prospective randomized
clinical TB drug efficacy trials. However, an overview of current data
on TB‐DM comorbidity in recent TB drugs trials is lacking. This over-
view may help to raise awareness on the inclusion of DM comorbidity
and could benefit the design of future TB drug trials. We therefore
aimed to systematically review the inclusion of DM comorbidity in
recent TB drug efficacy trials, with specific emphasis on differential
outcomes of TB‐DM overlap patients.2 | METHODS
2.1 | Study design
A systematic review was performed and reported according to the
Preferred Reporting Items for Systematic review and Meta‐Analyses(PRISMA) statement (Supporting information Appendix S1). The
review was registered at PROSPERO (registration number: 71203)
and is available online on https://www.crd.york.ac.uk/prospero/dis-
play_record.php? RecordID = 71203.2.2 | Information sources and search strategy
In this review, the PubMed, Science Direct and ClinicalTrials.gov data-
bases were systematically searched (in September 2017) for TB drug
trials published between 1 January 2012 and 12 September 2017
using combinations of the keywords “tuberculosis”, AND “drug” AND
“trial”. Full search criteria can be found in Supporting information
Appendix S2.2.3 | Inclusion criteria
The following eligibility criteria were applied for studies to be
considered for inclusion: (i) published in peer‐reviewed journals; (ii)
clinical trials or interventional studies of TB drug efficacy in TB
confirmed (i.e. sputum smear or culture positive) patients that have
been completed and published; and (iii) in English16 and reflecting an
original study. All criteria were required to be met for inclusion.
LUTFIANA ET AL. 32.4 | Exclusion criteria
Exclusion criteria were: (i) studies only assessing risk factors, bio-
markers (and not drugs) in theTB trials; (ii) reviews, comments, confer-
ence abstracts, case reports or editorials; and (iii) study designs other
than clinical trials.
2.5 | Study selection
Study screening based on title and abstract and selection based on
full‐text assessment was first performed by one researcher (N.L.) and
checked by a second researcher (M.Z.). Any discrepancies were solved
by consensus and/or consultation of a third researcher if needed.
2.6 | Data extraction and data items
Data extracted included the studies' first author, the year of publica-
tion, study design, study sample size, number and percentage of
comorbid DM patients, diagnostic criteria for DM, type of TB popula-
tion, drug(s) studied, and country where the trial was performed.
Again, data extraction was first performed by one researcher (N.L.)
and subsequently checked by a second researcher (M.Z.). Any discrep-
ancies were solved by consensus and/or consultation of a third
researcher if needed.
2.7 | Study measures and outcomes
The primary outcome of interest was the percentage of TB drug trials
performed around the world that included DM patients. Additionally,
results were assessed per continent. Exploratory, more descriptive
outcomes included differential outcomes of TB‐DM patients (if
reported). Chi‐square tests were performed to assess potential statis-
tical differences in inclusion (yes/no) of DM comorbidity across sub-
groups (e.g. type of TB and continent were trials were performed). A
P‐value <.05 was considered statistically significant.
2.8 | Assessment of reporting bias
To assess potential reporting bias, we searched for study protocols of
each study to check recruitment criteria of DM patients in the eligible
trials against reported population characteristics. If unclear, we
contacted the study authors to get more information about the DM
criteria and reported outcomes.3 | RESULTS
3.1 | Study selection
After duplicates were removed, a total of 1177 records were screened
based on abstract and title. We identified 54 potentially eligible full‐
text papers of which 13 studies were excluded after detailed review
(10 studies were noninterventional, and 3 assessed a diagnostic toolor the pharmacokinetics of TB drugs and not the efficacy of the TB
drug itself). A flow diagram is presented in Figure 1 and study charac-
teristics of the final selection of 41 trials are presented in Table 1.
Eligibility decisions for in‐ and excluded studies have been provided
in Supporting information Appendix S3. Of note, compared to our ini-
tial study protocol we did not apply the full‐text being available as an
inclusion criterion, given that we did not restrict ourselves to online
available full‐texts only but also contacted study authors to retrieve
full‐texts.3.2 | Study characteristics
The vast majority of TB drug trials was exclusively performed in Asia
(n = 15; 37%) and Africa (n = 13; 32%). North America (USA) and South
America (Brazil) contributed only one trial each, while others were
performed in Europe (n = 2, both in Georgia) or in multiple sites
around the world (n = 9). Study size varied between 31 patients for
a TB trial performed in Georgia25 and 1931 for a multicentre trial with
moxifloxacin.47 Drugs mostly studied were isoniazid, rifampicin,
pyrazinamide and ethambutol.3.3 | Overview of DM comorbidity in TB drug trials
Out of the included 41 trials, 12 (29.3%) reported DM comorbidity
among the study participants (Figure 2).
Nine trials (21.9%) clearly excluded patients with any DM comor-
bidity, 10 (24.4%) excluded only insulin‐dependent or uncontrolled
DM but did not report data of noninsulin dependent DM patients,
and 10 (24.3%) did not mention whether DM was included or
excluded. DM was included in 9 of the 15 (60%) trials performed in
Asia and in both European trials (Figure 2). In 12 of the 13 (92.3%)
African TB trials, patients with DM comorbidity were excluded. There
was a significant difference (P = .006) between DM inclusion in Asian
and African TB drug trials. Of the 12 trials that included patients with
DM comorbidity regardless of severity, 5 studies did not report the
diagnostic criteria for DM. Three studies used random blood glu-
cose.36,37,54 One study used fasting plasma glucose and 2‐hour oral
glucose tolerance test23 and 3 studies obtained DM comorbidity from
patients' history.38,39,48 The prevalence of DM among TB patients in
the 12 trials ranged from 0.7% in Mongolia and Ukraine54 to 36% in
South Korea19 with overall median DM prevalence of 12.3%. Natu-
rally, in the study that specifically focused on TB‐DM overlap, this
was 100%.23 Three out of 12 trials reporting DM comorbidity showed
that DM was the most common comorbidity.37-39 Of the 12 trials
reporting DM comorbidity, none of the studies assessed any potential
effects of DM on anti‐TB drugs outcomes. Of note, 6 out of 9 (67%)
drug trials for drug‐resistant TB included DM comorbidity in their
baseline characteristics, while only 4 out of the 32 (12.5%) drug‐
susceptibleTB trials included DM comorbidity in their baseline charac-
teristics, and this differed significantly (P = .003).
FIGURE 1 PRISMA flow diagram
4 LUTFIANA ET AL.4 | DISCUSSION
Data from this systematic review indicate that <1/3 recent TB drug
efficacy trials reported the inclusion of patients with DM comorbidity
regardless of DM severity. If included, diagnostic criteria for DM were
often unclear. Notably, inclusion of DM was relatively higher in MDR‐
TB drug trials and trials performed in Asia. Although DM patients were
included in some studies, no differential outcomes for DM‐TB overlap
patients were reported.
Asia has high DM prevalence amongTB patients; therefore, it is not
surprising that most trials that included DM comorbidity were con-
ducted in Asia, mainly China. China and India are 2 leading countries
that have piloted theTB‐DMcollaborative framework and have demon-
strated bidirectional screening for both diseases.57-59 Although India is
one of the pilot countries, most drug trials conducted in India had
unclear criteria for DM comorbidity, and one Indian trial even excluded
DM patients. Most trials that excluded DM comorbidity were con-
ducted in Africa. Notably, South Africa has high prevalence of TB, and
TB ranks third in diseases that causes life‐years lost,60 but none of the
TB drug trials conducted in South Africa screened for DM comorbidity.
For South Africa, this omission may be related to the relatively low
comorbid DM rates compared with, for example, comorbid human
immunodeficiency virus/acquired immune deficiency syndrome. How-
ever, the few TB drug trials conducted in America also did not assess
DM comorbidity, while DM rates in these continents are relativelyhigh.1 In particular, multidrug‐resistant TB (MDR‐TB) continues to be
a public health crisis and inMDR‐TB the importance of DMcomorbidity
seems more widely acknowledged. Indeed, in a meta‐analysis it was
shown that DM was an independent risk factor for MDR‐TB and, in
most drug‐resistant TB trials, DM comorbidity was more often
included.61 Regarding the effect of DM comorbidity to unfavourable
treatment of TB, none of the TB trials that included DM comorbidity
reported specific outcomes related to theTB‐DM subpopulation. A sys-
tematic review suggested a phase III clinical trial to ensure the safe use
of newTB drugs in diabetes patients.62 Indeed, there is still a lack of suf-
ficient data regarding pharmacokinetic and clinical data of TB drugs in
DM patients, despite the continuous growth of DM patients in the
future that will cause a further threat toTB control.
Some TB drug trials excluded insulin‐dependent DM patients.
Insulin‐dependent diabetes will usually reflect uncontrolled DM.63 As
TB patients with uncontrolled DM are more likely to fail on
treatment, trials that are specifically designed to show efficacy of a
new TB drug usually exclude those patients as they could compromise
trial results.64
Several underlying mechanisms to understand adverse treatment
outcomes of TB due to hyperglycaemia have been suggested.65,66
One mechanism is related to an altered immunological response67-69
which is important, but difficult to account for in TB treatment
decisions. Another factor that explains unfavourable treatment out-










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































8 LUTFIANA ET AL.review that assessed the pharmacokinetics of first‐line TB drugs
showed that age, sex, malnutrition, food intake, genetic factors and
comorbidities (mainly human immunodeficiency virus and diabetes)
could all play a role.70
Altered pharmacokinetics of anti‐TB drugs may warrant a need for
routine monitoring and modification of the regimens in patients with
DM. American Thoracic Society, Center for Disease Control and Pre-
vention, and Infectious Diseases Society of America guidelines suggest
early identification of patients at increased risk of relapse such as
those with DM71 as well as therapeutic drug monitoring (TDM).
TDM does allow for timely, informed decisions regarding the need
for dose adjustment when necessary. TDM is considered to be helpful
in situations in which clinicians are confronted with drug malabsorp-
tion, drug under‐dosing, or clinically important drug–drug or drug–
disease interactions, such as diabetes comorbidity.72
To our knowledge, this is the first systematic review specifically
focusing on the inclusion of DM in TB drug trials. Major strengths are
the search within 3 different databases, double checking of inclusion
and data extraction and reporting according to the standardized
PRISMA statement. Also, some limitations need to be mentioned. First,
given the focus on English languagemanuscripts and our own restricted
language knowledge, we had to exclude the few trials that were only
published in a local language. These trials could potentially be informa-
tive but may often be less generalizable as the larger multicountry trials.
Second, the studies included in this review used different diagnostic
criteria for DM that could induce the risk of over‐ or under representa-
tion of DM patients among studies. Also, we should consider that if
studies did not explicitly listed DM as an exclusion criterion, it may well
be that DM patients were eligible but were not included in the trial.
Third, no meta‐analysis was performed because we felt that simply
combining all rates would be less informative than providing separate
DM inclusion rates by region/continent. Fourth, in the PubMed search,
we applied a full‐text available filter (see Supporting information
Appendix S2). This could have excluded some full manuscripts that only
had an abstract available in PubMed. Retrospectively, we have checked
the impact of this filter. In the search without the filter, 21 additional
hits (equalling 3.7% more hits) were found, although, after inspection,
none were eligible. Finally, we could not assess reporting bias as clinical
trials around the world can be registered in many different databases
and we received little response from contacting the study authors.
Therefore, comparing published trials with registered trials was not
feasible.
Regarding future research and policies, it is important for TB drug
trials to screen for DM comorbidity, aim for a representative, real‐life,
DM percentage according to the location and appropriately diagnose
DM. Alternatively, a separate multicentre trial in diabetic patients
could be considered where also more emphasis can be placed
on diabetes‐specific outcomes such as hypoglycaemias. Intensified
research and development of TB drugs, particularly in the context of
comorbidities such as DM, play a crucial role to improve TB control
and contribute to reductions in TB incidence and mortality required
to reach global TB targets by 2035, one of the pillars of World Health
Organization's Post‐2015 Global TB Strategy.16
FIGURE 2 Inclusion status of diabetes
mellitus (DM) in tuberculosis drug trials 2012–
2017 (total n = 41)
LUTFIANA ET AL. 9Including DM comorbidity in TB drug trials will allow for the study
of possible DM‐TB drug–drug and drug–disease interactions that can
alter the pharmacokinetics, safety and clinical effects of the TB drugs.
Eventually, these findings will enable us to assess TB‐DM patients'
individual need for personalize treatment options and lead to better
real‐world TB‐DM outcomes and possibly lower resistance rates.5 | CONCLUSION
To conclude, current inclusion of DM comorbidity in recent TB drug
efficacy trials is suboptimal compared with its increasing prevalence
and significance. Considering the considerable prevalence and impact
of DM comorbidity, the inclusion of patients with DM in future TB
efficacy drug trials warrants increased attention and requires a joint
effort of trialists, clinicians and policy makers alike.
5.1 | Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to
corresponding entries in http://www.guidetopharmacology.org, the
common portal for data from the IUPHAR/BPS Guide to
PHARMACOLOGY.73
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